Atiqah Amran,Atiqah AmranChing Yee Tan,Ching Yee TanKa-Liong Tan,Ka-Liong TanRanald Malcom Ho,Ranald Malcom HoAnil Kumar Anand,Anil Kumar AnandChuei Wuei Leong2024-05-282024-05-2820212022-1-27Amran, A., Tan, C.Y., Tan, K.-L., Ho, R.M., Anand, A.K. and Leong, C.W. (2021), Pharmacokinetics and Bioequivalence Study of a New Branded Generic Moxifloxacin Tablet Among Healthy Volunteers. Clinical Pharmacology in Drug Development, 10: 1514-1518. https://doi.org/10.1002/cpdd.9642160-76482224-1210.1002/cpdd.964https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.964https://www.scopus.com/record/display.uri?eid=2-s2.0-85107598778&origin=resultslist&sort=plf-f&src=s&st1=Pharmacokinetics+and+Bioequivalence+Study+of+a+New+Branded+Generic+Moxifloxacin+Tablet+Among+Healthy+Volunteers&sid=31be55ee0bda8589898f4899befb35db&sot=b&sdt=b&sl=126&s=TITLE-ABS-KEY%28Pharmacokinetics+and+Bioequivalence+Study+of+a+New+Branded+Generic+Moxifloxacin+Tablet+Among+Healthy+Volunteers%29&relpos=0&citeCnt=1&searchTerm=https://oarep.usim.edu.my/handle/123456789/9352Clinical Pharmacology in Drug DevelopmentVolume 10, Issue 12, Pages 1514 - 1518December 2021A newly developed branded generic of a moxifloxacin (MOX) 400-mg tablet formulation was manufactured prior to this study. A bioequivalence (BE) study was done to assess the pharmacokinetics of the formulation using a randomized, open-label, 2-period crossover, 2-sequence, and single-dose experiment. Thirty healthy male volunteers were recruited. The test formulation, Flonoxin 400 mg, was compared with the reference formulation, Avelox 400 mg. The pharmacokinetic parameters of MOX were calculated based on the plasma drug concentration-time profile. Noncompartmental analysis was performed to determine its safety and tolerability. The 90% confidence intervals (CIs) were 88.5%-104.6%, 96.1%-101.1%, and 96.8%-100.7% for Cmax, AUC0-t, and AUC0-inf, respectively. All CIs were within the 80.0%-125.0% boundary, thus fulfilling the acceptable BE criteria according to the ASEAN guidelines.enbioequivalence study; moxifloxacin; new branded genericsArticle151415181012